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Postrenal transplantation diabetes mellitus (PTDM), or new-onset diabetes after organ transplantation, is an important chronic 
transplant-associated complication. Similar to type 2 diabetes, decreased insulin secretion and increased insulin resistance are 
important to the pathophysiologic mechanism behind the development of PTDM. However, β-cell dysfunction rather than insu-
lin resistance seems to be a greater contributing factor in the development of PTDM. Increased age, family history of diabetes, 
ethnicity, genetic variation, obesity, and hepatitis C are partially accountable for an increased underlying risk of PTDM in renal 
allograft recipients. In addition, the use of and kinds of immunosuppressive agents are key transplant-associated risk factors. Re-
cently, a number of genetic variants or polymorphisms susceptible to immunosuppressants have been reported to be associated 
with calcineurin inhibition-induced β-cell dysfunction. The identification of high risk factors of PTDM would help prevent PTDM 
and improve long-term patient outcomes by allowing for personalized immunosuppressant regimens and by managing cardio-
vascular risk factors. 
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INTRODUCTION
During the immediate period after solid organ transplantation, 
rejection of the transplanted organ as well as the short-term 
survival rate of the patient is of primary concern. Overcoming 
the shortcomings of currently available surgical techniques 
and immunosuppressants would allow for a longer life expec-
tancy in more patients. Accordingly, greater emphasis has been 
placed on caring for chronic transplant-associated morbidi-
ties, which are the primary determinant of expectancy and 
quality of life in the long-term post-transplantation periods. 
The increased prevalence of macrovascular events in transplant 
recipients compared to non-transplant subjects remains a piv-
otal challenge to overcome. Among the established risk factors 
for the development of cardiovascular events in transplant re-
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cose homeostasis in kidney transplant recipients. Therefore 
this review focuses on what is currently known about how ge-
netics and pancreatic β-cell dysfunction related to the devel-
opment of diabetes in kidney recipients. 
INCIDENCE OF POSTRENAL 
TRANSPLANTATION DIABETES MELLITUS 
Hyperglycemia after renal transplantation leads to the devel-
opment of microvascular morbidity as well as accelerated mac-
rovascular events, resulting in reduced recipient survival [1]. 
In this regard, aggravation of pre-existing diabetes as well as 
new-onset transplant-associated hyperglycemia encompass-
ing new onset diabetes mellitus (DM), impaired fasting glu-
cose (IFG), and impaired glucose tolerance (IGT) have been 
introduced as gluco-metabolic targets in an effort to reduce 
the risk of developing chronic transplant-associated morbidity 
and mortality by implementing proper management approach-
es during pre- and post-transplant stages [2]. Postrenal trans-
plantation diabetes mellitus (PTDM), first described by Starzl 
et al. [3] in 1964, is defined as new-onset diabetes after solid 
organ transplantation. The definition of diabetes according to 
the American Diabetes Association (ADA) is a fasting plasma 
glucose [FPG] ≥7.0 mmol/L or a 2-hour post-load glucose 
≥11.1 mmol/L, and this is routinely adopted when diagnosing 
PTDM. However, the incidence and prevalence of PTDM var-
ies among studies depending on the criteria used to diagnose 
diabetes, the usage or kinds of immunosuppressants, charac-
teristics of the subject population, and time after transplanta-
tion [4]. In the 1970s and early 1980s, steroids were considered 
the gold standard drug-of-choice and 40% to 60% of transplant 
recipients developed DM [5,6]. Even with the advent of cyclo-
sporine A (CsA) in 1978, the prevalence of PTDM ranges 
widely from 5% to 45% [7-12], which is 2 to 9 times more than 
that of DM in an age- and sex-matched general population. A 
meta-analysis involving 19 observational studies and controlled 
trials reported that the rates of PTDM in the first post-trans-
plantation year range from 2% to 50%. Two of the largest epi-
demiologic studies investigating the incidence of PTDM in 
subjects on the waiting list for renal transplantation and trans-
plant recipients [13,14] demonstrated a 6% annual baseline 
incidence of new onset diabetes for the wait-listed subjects, 
and a 14% to 16% increase in the incidence of PTDM during 
the first post-transplantation year for transplant recipients. In 
the Korean population, it was previously reported that the 
overall incidence of PTDM was 39% at 1 year after transplan-
tation and 35.1% at 7 years after transplantation [15]. Based on 
these results, PTDM might be especially accelerated in the first 
few post-transplantation months by the superimposition of 
transplant-related factors on baseline risks. 
TRANSPLANT-ASSOCIATED RISK FACTORS 
AND TRADITIONAL TYPE 2 DIABETES RISK 
FACTORS OF PTDM
The risk factors associated with PTDM have been examined in 
many studies. Underlying baseline risk factors such as in-
creased age, family history of diabetes, ethnicity, genetic varia-
tion, obesity, and hepatitis C are partially accountable for an 
increased underlying risk of PTDM in renal allograft recipients 
[16-18]. Non-modifiable risk factors of PTDM appear to be 
greater for patients who are older at the time of transplanta-
tion and have a familial history of diabetes [19]. Kidney trans-
plant recipients older than 40 years of age are at greater risk of 
PTDM than younger recipients [11]. Gaining weight after 
transplantation, particularly among kidney transplant recipi-
ents, and infection with the hepatitis C virus [20] are modifi-
able risk factors for the development of PTDM. Similar to type 
2 diabetes (T2D), weight gain after transplantation leads to in-
sulin resistance [21] resulting in the development of PTDM. 
  In terms of transplant-related risk factors, usage and types 
of immunosuppressive agents are key to the aggravation or 
development of DM. PTDM is a major adverse effect of im-
munosuppressants. The diabetogenic effect of glucocorticoids, 
which has been well known since the early transplantation era, 
mainly results from both decreased peripheral glucose utiliza-
tion and increased hepatic glucose production. The introduc-
tion of the 2nd generation of immunosuppressants of calci-
neurin inhibitors such as CsA and tacrolimus (Tac) into the 
field of transplantation has improved the outcome of organ 
transplants. However, their widespread therapeutic use is hin-
dered by numerous reciprocal side effects shared between both 
drugs. Among them, new onset DM after transplantation, also 
known as PTDM, is of particular concern because of its fre-
quent occurrence [22] and its associations with increased risk 
of cardiovascular diseases and lower survival rates.
  Although the clinical features of T2D, such as insidious de-
velopment, asymptomatic periods, etc., are similar to those of 
PTDM, some questions still remain regarding the incidence of 
PTDM among different ethnic groups. Interestingly, non-Cau-201
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casian kidney transplant recipients such as African-Ameri-
cans, Hispanics, and Koreans are at greater risk of developing 
PTDM. These differences might be partially related to the 
pathophysiological development or aggravation of diabetes. 
The pathophysiologic nature of T2D is characterized by a pro-
gressive decline in pancreatic β-cell function and worsening 
insulin resistance, resulting in the failure of islets to respond to 
oral anti-diabetic drugs. However, the major determinant fac-
tors of PTDM remain controversial and there is some debate 
regarding whether the pathophysiology of PTDM is the result 
of decreased insulin secretion, increased insulin resistance, or 
both. For example, Ekstrand et al. [23] stated that insulin re-
sistance and decreased insulin secretion may both be respon-
sible, while Midtvedt et al. [24] suggested that insulin resis-
tance may be the major contributor, and Shimizu et al. [25] re-
ported that insulin resistance was improved after transplanta-
tion. Finally, in a well-designed 6-year prospective study, Ha-
gen et al. [26] reported that impaired insulin secretion was the 
dominant mechanism for the development of PTDM. We have 
demonstrated that β-cell dysfunction was a major contribut-
ing factor to the development of PTDM in Korean subjects 
[15], which is consistent with Hagen et al.’s results. As we pre-
viously described, hyperglycemia after transplantation might 
be accelerated by the superimposition of transplant-related 
factors on baseline risks. Considering the characteristics of 
Korean patients with T2D, whose secretory β-cell dysfunction 
was a major contributing factor to the development and ag-
gravation of hyperglycemia [27,28], different pharmacokinetic 
responses may augment the diabetogenic impact of immuno-
suppressants and superimpose upon conventional susceptible 
risks in the Korean population. In this regard, we also reported 
that the interaction between traditional genetic risk factors and 
transplant-associated risk factors such as calcineurin inhibi-
tors plays an important role in the augmentation of established 
and new onset diabetes [29].
  The association between PTDM and calcineurin inhibitor 
drugs is well-established. Previous in vitro studies on purified 
islets and insulin-producing β-cells have proposed several dia-
betogenic actions for CsA and Tac. Both drugs impair insulin 
secretion [30-33], decrease insulin content of the β-cell [34,35] 
and impair insulin transcription [36,37], although the primary 
mechanisms are not yet fully understood. In insulin-secreting 
cells, calcineurin is involved in the stimulation of insulin gene 
transcription through the activation of the transcription factor 
nuclear factor of activated T-cells (NFAT) [38]. Indeed, mice 
deficient in calcineurin B1 were shown to develop DM due to 
insufficient insulin production, while transgenic expression of 
constitutively active NFAT protected against DM [39]. In an-
other study on immunosuppressants, rapamycin inhibited the 
mammalian target of rapamycin without affecting calcineurin 
activity, and also inhibited glucose-stimulated insulin secretion 
(GSIS) in β-cells [40,41]. Although the therapeutic ranges of 
Tac and rapamycin are comparable, the potency of rapamycin 
in inhibiting insulin secretion seemed to be much lower than 
that of Tac in our study [29]. This may partly explain why ra-
pamycin has less diabetogenic activity. However, the role of ra-
pamycin in PTDM is still under investigation [17,42]. Recent-
ly, the suppression of carbohydrate metabolism by rapamycin 
was suggested as a possible mechanism for the inhibition of 
insulin secretion [43]. However, the mechanism of action of 
rapamycin in the insulin secretory pathway is largely unknown.
PATHOPHYSIOLOGY OF PTDM: β-CELL 
DYSFUNCTION RATHER THAN INSULIN 
RESISTANCE 
Diabetes is caused by an imbalance in insulin production and 
peripheral insulin sensitivity. Despite some controversy, insu-
lin secretory dysfunction is thought to be the dominant mech-
anism for the development of PTDM. We found that β-cell 
dysfunction plays a major role in the development of PTDM, 
which is consistent with previous reports [15,21]. On the issue 
of ‘Diabetes Care’ [15], we enrolled a total of 77 subjects with 
normal glucose tolerance (NGT), and an oral glucose toler-
ance test (OGTT) was performed 1 week before transplanta-
tion and repeated at 1 and 7 years after transplantation [15]. 
The overall incidence of PTDM was 39% at 1 year and 35.1% at 
7 years post-transplantation. 
  The following conclusions were drawn based on the results 
of these studies: first, the fasting and 2-hour plasma glucose 
levels before transplantation in the IGT and PTDM after trans-
plantation groups were significantly higher than those in the 
NGT after transplantation group. Second, patients with de-
creased insulin-secretory capacity, rather than decreased insu-
lin sensitivity, were predisposed to developing PTDM. Com-
pared with values before transplantation, the indices of insulin 
secretion and insulin sensitivity deteriorated at 1 year after 
transplantation. The insulin sensitivity index (ISI), represent-
ing insulin sensitivity, was not statistically different among 
groups after transplantation. However, the area under the curve 202
Lee HC
Diabetes Metab J 2012;36:199-206 http://e-dmj.org
of insulin on OGTT, representing insulin secretory function, 
was significantly lower in the PTDM group than in the NGT 
group. Proinsulin and proinsulin/insulin ratios have been pro-
posed as indices for reduced maximum β-cell secretory capac-
ity in patients with type 1 and type 2 diabetes [44,45]. Maxi-
mum β-cell secretory capacity plays a pivotal role in the re-
sponse to glucose loading, which is associated with deteriora-
tion in glucose tolerance. In our study, proinsulin/insulin ra-
tios in the IGT and PTDM groups were significantly higher 
than in the NGT group at both pre- and post-transplantation 
periods. Taken together, this indicates that β-cell dysfunction 
was a more important factor for the development of PTDM.
GENETIC RISK FACTORS OF PTDM AND 
CLINICAL IMPLICATIONS OF ZINC 
TRANSPORTER-8 GENE IN RENAL 
TRANSPLANTATION 
PTDM may reflect a genetic predisposition to diabetes influ-
enced by multiple environmental factors. Twenty-six percent 
of patients with a family history of diabetes develop PTDM, 
while only 14% of patients without a family history of diabetes 
develop PTDM [46]. This finding suggests that genetic variants 
typically associated with T2D are also likely associated with 
PTDM. However, only a few of the genetic polymorphisms as-
sociated with T2D have been studied in detail in transplant 
patients. Some studies have shown a significant association 
between PTDM and genetic polymorphisms. These polymor-
phisms were associated with genes involving insulin secretion 
(KCNJ11, HNF4A, NFATc4, ENPP1/PC-1 [K121Q], CCL5, 
VDR) [47-52], insulin resistance (adiponectin, adiponectin re-
ceptor 1, PAI-1) [53-55], and oxidative stress (glutathione S-
transferase gene, SOD) [56,57]. One functional study and our 
three genetic association studies comprising a renal allograft 
cohort found that TCF7L2, a T2D susceptibility gene, led to a 
two-fold increase in the risk of T2D. In addition, we found 
that the TCF7L2 rs7903146 genetic variation is also signifi-
cantly associated with an increased risk of developing PTDM 
in kidney transplant recipients [58]. Zinc found in the zinc 
transporter-8 (ZnT-8) gene is involved in modulating insulin 
secretion. The R325W (rs13266634) non-synonymous poly-
morphism in the islet-specific zinc transporter protein gene 
SLC30A8 is associated with T2D and also may be associated 
with a defect in insulin secretion. To investigate the association 
between genetic variations in the SLC30A8 gene and PTDM 
in renal-transplant recipients [59], we recruited a total of 624 
renal-allograft recipients without a documented history of di-
abetes. The prevalence of PTDM was 33.8% in patients with 
the R/R genotype, 26.8% in those with the R/W genotype, and 
19.8% in those with the W/W genotype. In addition, a strong 
association between the number of W alleles and PTDM risk 
reduction (P=0.007) was found. Patients with at least one W 
allele had a lower risk of PTDM compared to those with the R/
R genotype (R/W RR, 0.78, P=0.126; W/W RR, 0.52, P=0.007). 
The effect of the SLC30A8 genotype remained significant even 
after adjusting for age, gender, body weight gain, and type of 
immunosuppressant (R/W hazard ratio [HR], 0.77, P=0.114; 
W/W HR, 0.58, P=0.026). Therefore the SLC30A8 rs13266634 
gene variation appears to be associated with protection against 
the development of PTDM in renal-allograft recipients. 
  There is an association between PTDM and 17 single nucle-
otide polymorphisms (SNPs) located within 15 genes. Genome-
wide association studies determined that these genes were re-
lated to diabetes susceptibility [60]. We found an association 
between the development of PTDM and the following SNPs: 
HHEX (rs1111875, rs7923837, and rs5015480), CDKAL1 
rs10946398, CDKN2A/B rs10811661, IGF2BP2 rs4402960, 
FTO rs8050136, WFS1 rs734312, JAZF1 rs864745, CDC123/
CAMK1D rs12779790, TSPAN8 rs7961581, THADA 
rs7578597, ADAMTS9 rs4607103, NOTCH2 rs1092391, and 
KCNQ1 rs2237892. Six loci were significantly associated with 
PTDM development: HHEX rs1111875 (odds ratio [OR], 1.47; 
P=0.007), HHEX rs7923837 (OR, 2.32; P=0.014), HHEX 
rs5015480 (OR, 1.59; P=0.003), CDKAL1 rs10946398 (OR, 
1.43; P=0.008), CDKN2A/B rs10811661 (OR, 1.33; P=0.039), 
and KCNQ1 rs2237892 (OR, 1.46; P=0.009).
  Recently, we investigated the functional aspect of the zinc 
transporter gene, based on the hypothesis that the polymor-
phic residue at position 325 of ZnT-8 might determine suscep-
tibility to CsA suppression of insulin secretion [29]. INS-1E 
cells expressing the W325 variant showed enhanced GSIS and 
were less sensitive to CsA suppression of GSIS. A reduced 
number of insulin granule fusion events accompanied the de-
crease in insulin secretion in CsA-treated cells expressing ZnT-
8 R325; however, ZnT-8 W325-expressing cells exhibited re-
sistance to the dampening of insulin granule fusion by CsA 
and transported zinc ions into secretory vesicles more efficient-
ly. Both Tac and rapamycin caused similar suppression of GSIS 
in cells expressing ZnT-8 R325. However, cells expressing ZnT-8 
W325 were resistant to Tac, but not to rapamycin. Overexpres-203
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sion of the Down’s syndrome candidate region-1 (DSCR1), an 
endogenous calcineurin inhibitor, and subsequent calcineurin 
inhibition significantly reduced GSIS in cells expressing the 
R325 but not the W325 variant, suggesting that differing sus-
ceptibility to CsA may be due to different interactions with 
calcineurin. These data suggest that the ZnT-8 W325 variant is 
protective against CsA-induced suppression of insulin secre-
tion. Tolerance of ZnT-8 W325 to calcineurin activity may ac-
count for its protective effect in PTDM.
CONCLUSIONS
DM is a serious and frequent complication of renal transplan-
tation. Although DM ultimately results from decreased insulin 
secretion and increased insulin resistance, our data suggest 
that β-cell dysfunction, rather than insulin resistance, may be 
the main contributing factor in the development of PTDM. 
PTDM is not always permanent and may resolve within weeks 
or months, sometimes without treatment. The aforementioned 
risk factors seem to be related to the different courses of PTDM. 
The ability to predict a patient’s risk for developing PTDM 
would be of considerable benefit in selecting appropriate im-
munosuppressive regimens for individuals.
  Genotyping diabetes-related polymorphisms is one possible 
method for predicting a patient’s risk for developing PTDM. 
Our data suggest that genetic variations such as TCF7L2, SL-
C30A8, HHEX, CDKAL1, CDKN2A/B, and KCNQ1 are asso-
ciated with PTDM in Korea. Notably, SLC30A8 encodes for 
β-cell-specific ZnT-8. The same allelic variant (which is a sub-
stitution of tryptophan for arginine at residue 325) of ZnT-8 is 
also associated with reduced incidence of PTDM in renal al-
lograft recipients (Fig. 1). A single nucleotide substitution in 
SLC30A8 confers resistance to CsA-induced β-cell dysfunc-
tion by altering susceptibility to calcineurin inhibition. Our 
data suggest that ZnT-8 might be an important molecule con-
necting calcineurin inhibition by CsA to downregulation of 
β-cell insulin secretion, and this signaling pathway might be a 
new therapeutic target for the treatment of CsA-induced β-cell 
complications that occur after organ transplantation.
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